| Basics |
Amgen Inc.
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
|
| IPO Date: |
January 2, 1990 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$158.92B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.37 | 0.99%
|
| Avg Daily Range (30 D): |
$3.05 | 1.10%
|
| Avg Daily Range (90 D): |
$3.58 | 1.23%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
4.84M |
| Avg Daily Volume (30 D): |
2.18M |
| Avg Daily Volume (90 D): |
2.26M |
| Trade Size |
| Avg Trade Size (Sh.): |
134 |
| Avg Trade Size (Sh.) (30 D): |
40 |
| Avg Trade Size (Sh.) (90 D): |
40 |
| Institutional Trades |
| Total Inst.Trades: |
112,927 |
| Avg Inst. Trade: |
$6.19M |
| Avg Inst. Trade (30 D): |
$29.83M |
| Avg Inst. Trade (90 D): |
$34.27M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
20 |
| Market Closing Trades |
| Avg Closing Trade: |
$64.3M |
| Avg Closing Trade (30 D): |
$132.94M |
| Avg Closing Trade (90 D): |
$166.39M |
| Avg Closing Volume: |
386.65K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$3.22
|
$5.27
|
|
Diluted EPS
|
|
$3.2
|
$5.22
|
|
Revenue
|
$
|
$ 8.15B
|
$ 8.5B
|
|
Gross Profit
|
$
|
$ 5.18B
|
$ 5.19B
|
|
Net Income / Loss
|
$
|
$ 1.73B
|
$ 2.83B
|
|
Operating Income / Loss
|
$
|
$ 1.18B
|
$ 2.05B
|
|
Cost of Revenue
|
$
|
$ 2.97B
|
$ 3.31B
|
|
Net Cash Flow
|
$
|
$ -3163M
|
$ -290M
|
|
PE Ratio
|
|
|
|
|
|
|
